Loading
A phase 2 trial of Durvalumab, Olaparib, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) is a phase 2 interventional study registered as NCT03775486 by AstraZeneca, with 401 participants enrolled, started 2018-12-21 and due to reach its primary completion in 2021-01-11. Interventions recorded: Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin. Conditions listed: Non-small Cell Lung Cancer NSCLC. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Durvalumab, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
Shares PARP inhibitors, Olaparib, Durvalumab, AstraZeneca.
Shares PARP inhibitors, Olaparib, Durvalumab, AstraZeneca.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
Shares PARP inhibitors, Olaparib, Pemetrexed, Carboplatin.
Shares Pemetrexed, Durvalumab, Gemcitabine, AstraZeneca.
Shares PARP inhibitors, Olaparib, Durvalumab, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/